CAG-Targeting amiRNA Allele-Selective Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi reagents for treating diseases caused by trinucleotide CAG repeat expansions, such as Huntington's disease, lack allele-selectivity, leading to off-target effects and side effects due to non-selective silencing of both normal and mutant transcripts.
Innovation Solution
Development of CAG-targeting artificial miRNA (amiRNA) with two or three interruptions in the CUG sequence, forming mismatches with target sequences to reduce off-target effects while preserving allele-selectivity, using a nucleic acid molecule with a specific duplex and loop structure, and delivery via a recombinant AAV vector.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CAG-targeting RNAi reagents are used to silence mutant transcripts, then allele-selectivity is improved, but off-target effects increase due to binding to complementary sequences in human transcriptome
Solution Approach 1:
The patent introduces selective modifications at specific local positions within the amiRNA sequence to create A:A mismatches with the CAG repeat region. This localized modification strategy allows the reagent to maintain high allele-selectivity for mutant transcripts while reducing binding to off-target sequences with complementary CAG repeats, thereby resolving the contradiction between precision and harmful effects.
Solution Approach 2:
The patent modifies the sequence parameters of the amiRNA by introducing interruptions in the CUG sequence at specific positions. These parameter changes alter the binding characteristics of the reagent, enabling it to distinguish between mutant and wild-type transcripts more effectively while minimizing off-target binding, thus resolving the contradiction between allele-selectivity and off-target effects.
2Device complexity
If non-selective silencing strategy is used to target both normal and mutant transcripts, then simplicity of treatment is improved, but safety profile deteriorates due to loss of normal protein function
Solution Approach 1:
The patent employs local modifications in the amiRNA sequence that create specific A:A mismatches with the CAG repeat region. This localized differentiation allows the reagent to selectively silence only mutant transcripts while preserving normal protein function, thereby resolving the contradiction between treatment simplicity and safety.
Solution Approach 2:
Instead of using a non-selective approach that silences both mutant and wild-type transcripts, the patent inverts the strategy by introducing selective modifications that enable discrimination between mutant and wild-type transcripts. This inversion allows for targeted silencing of mutant transcripts only, maintaining safety while preserving the simplicity of the treatment approach.
3Measurement precision
If selective modification is introduced into amiRNA sequence to create A:A mismatch, then allele-selectivity is improved, but device complexity increases due to specific sequence requirements
Solution Approach 1:
The patent segments the amiRNA sequence into distinct functional regions: a 5' arm, a 3' arm, and a loop region. The selective modifications are introduced at specific positions within these segments, particularly in the 5' arm where A:A mismatches with CAG repeats occur. This segmentation allows for systematic design and optimization of allele-selectivity without overwhelming complexity.
Solution Approach 2:
The patent systematically varies sequence parameters such as the position and type of interruptions in the CUG sequence, as well as the specific nucleotides introduced to create A:A mismatches. By optimizing these parameters, the patent achieves high allele-selectivity while managing the complexity of sequence design through structured parameter variation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces off-target sites in the human transcriptome and achieves preferential silencing of mutant huntingtin protein, maintaining normal protein levels, thereby improving safety and efficacy in treating neurodegenerative diseases.
Implementation Method 1
a nucleic acid molecule composed of a duplex and loop, in which one of the duplex strands, the guide strand, comprises a sequence chosen from SEQ ID NO. 1-4, and the other strand of the duplex, the passenger strand, is at least 80% complementary to the guide strand
Implementation Method 2
The introduction of selective modification into amiRNA sequence creates an A: A mismatch with mRNA target and activates the mechanism of translation inhibition
Data Source
AI summary
A nucleic acid molecule composed of a duplex and loop, in which one of the duplex strands, the guide strand, comprises a sequence chosen from SEQ ID NO. 1-4, and the other strand of the duplex, the passenger strand, is at least 80% complementary to the guide strand, wherein the nucleic acid molecule forms a hairpin structure in a cell.